详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ 中华系列

作者：

单位： [1]China Japan Friendship Hosp, Dept Endocrinol, Beijing 100029, Peoples R China [2]Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian 710032, Shaanxi, Peoples R China [3]Nanjing Drum Tower Hosp, Dept Endocrinol, Nanjing 210008, Jiangsu, Peoples R China [4]Beijing Tongren Hosp, Dept Endocrinol, Beijing 100730, Peoples R China [5]Wuhan Union Hosp, Dept Endocrinol, Wuhan 430022, Hubei, Peoples R China [6]Shanghai Changzheng Hosp, Dept Endocrinol, Shanghai 200003, Peoples R China [7]Tianjin Med Univ, Dept Endocrinol, Metab Dis Hosp, Tianjin 300070, Peoples R China [8]Zhongshan Univ, Dept Endocrinol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China

出处：

DOI：

ISSN：

关键词： biphasic insulin aspart 30 diabetes mellitus type 2 weight gain hypoglycaemia China

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2008]版：

大类 | 4 区医学

小类 | 4 区医学：内科

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：内科

JCR分区：

出版当年[2007]版：

Q3 MEDICINE, GENERAL & INTERNAL

最新[2023]版：

Q1 MEDICINE, GENERAL & INTERNAL

影响因子： 最新[2023版] 7.5 最新五年平均[2021-2025] 4.9 出版当年[2007版] 0.636 出版当年五年平均[2003-2007] 0.685 出版前一年[2006版] 0.615 出版后一年[2008版] 0.858

第一作者：

第一作者单位： [1]China Japan Friendship Hosp, Dept Endocrinol, Beijing 100029, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes [2]Treat-to-target comparison between once daily biphasic insulin aspart 30 and insulin glargine in Chinese and Japanese insulin-naive subjects with type 2 diabetes [3]Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs [4]Predictors of achieving HbA(1c) < 7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study [5]15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes [6]Better glycaemic control for 30,171 insulin-naive patients with type 2 diabetes after starting biphasic insulin aspart 30/70 (BIAsp 30) therapy: IMPROVE (TM) study subgroup analysis [7]Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study [8]Thrice daily biphasic insulin aspart 30 regimen: another therapeutic option for Chinese patients with Type 2 diabetes [9]IMPROVEMENTS IN QUALITY OF LIFE ASSOCIATED WITH BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS IN CHINA: RESULTS FROM THE A1CHIEVE OBSERVATIONAL STUDY [10]Safety and Effectiveness of Biphasic Insulin Aspart 30 in Different Age-Groups: A(1)chieve Sub-Analysis